Member Info for loskins

I'm quite independent in my investment and like to do my own research but I do like to to listen to Vox markets and this came up with an interview with a guy from rockwood strategic investments.....totally sold it to me, never heard of the company before, totally off radar but done my research now and it seems on paper to be as solid as they come in a hot sector. So I'm in and there's always the bonus of a divi !!!

Agreed, great deal making by Tosca and possibly Mediclinic. It would have to be a pretty hefty counter proposal for them to loosen their firm grip over Spire. Ironically Tosca declined Ramsey's offer in 2021 of the same valuation stating it undervalued the business !! Reading between the lines I really do believe the wording of today's RNS was geared towards weeding out any other potential suitors. I'm gonna carry on holding to see what happens plus there is a divi to consider too

Https://news.sky.com/story/mark-kleinman-blog-see-the-latest-stories-from-sky-news-city-editor-13475361

I suspect trading algos are destroying value here, it's an easy target. Failed takeover, previous profit warning, NHS contracting uncertainty, long winded strategic process, poor sentiment, poor share price performance,...all the dominoes are lined up so no surprise its getting shorted. Value is entirely disengaged from NAV but it doesn't matter to the shorters because at this precise moment wealth can be gained from financial and reputational destruction of a once highly regarded company. If this quality UK company does end up getting sold for a fraction of its true worth to a foreign entity then that would feel so wrong. Personally I would prefer Spire to fight off any potential suitors unless that is the market cap is at least double it's current price.

Https://www.londonstockexchange.com/news-article/market-news/announcement-made-following-a-related-announcement/17513585

Gotta be a positive sign as Titan look to raise upwards £7B of cash, I've ought another tranche.

Triton raising cash

https://news.sky.com/story/mark-kleinman-blog-see-the-latest-stories-from-sky-news-city-editor-13475361

Spot on Asartara, their playing the sp perfectly. Took out a whole host of stop losses today around lunch time...

It's pleasing to note that none you believe the current slide in the share price has nothing to do with the upheaval going on in the world at present, that FTSE 100 is down 2.7% today and generally as a rule company takeovers can be disrupted or put on hold during all of this turbulence. Just a though ?

Drift in price is possibly due to extension date been advanced to 21st March, reckon we might see some action around results day 5th March.

Is this another Petrofac ? I'm out with the little I have remaining..nice 70% loss

You never know, might get a snippet from the press this weekend. Something along the lines of "Spire Healthcare closes the window on further potential offerers after multiple candidates show an interest in acquiring the company"...now that's a headline I wouldn't mind waking up to on Sunday morning !!!

Despite the poor immediate forecast in the recent trading update, one factor that may well have gone unnoticed is the 18 month extension of the debt facilities. It's a common process to indicate PE activity, role the debt so it's not an immediate concern and it's a good sign that some strong agreements are already in place. Hoping to see an initial offer around the £2.40 mark in the coming month but we may be looking at an all share merger.

Mediclinic bought their original stake in Spire in June 2015 paying a whooping £3.60 a share then ultimately went on to offer £3.15 for the company in 2017 which was rejected at the time by Spire. Mediclinic supported Ramsey Healthcare's bid in May 2021 at £2.50 which was accepted by the board this time but ultimately rejected by other major shareholders who were holding out for £3.40 a share. I would be gobsmacked if Mediclinic or anyone else for that matter managed to squeeze in an accepted bid in the £2 region. I believe this current instability in the share price is more down to a drawn out tendering process and a flat trading update. I suspect and hope prospects may liven up a little after the deadline date for due diligence passes on 20th Jan though no bid may be forthcoming leaving activist shareholders with the dilemma as to what to do with their existing holdings.

Considering Spire have rejected previous bids of £3 in 2018 and £2.50 in 2021, I wouldn't have thought they were in a precarious enough position to accept anything below these valuations. The recent profit warning has obviously stymied expectations but I would still expect a takeover value to be much higher than the current valuation. CEO Justin Ash and largest shareholder Mediclinic International have a much higher average on share purchases and would surely not sell out at a great loss.

Aye, but who have they sold them to. Have they sold them directly into the market hence the big drop or have they been bought up by a potential suitor. The mystery goes on..I'm happy to buy at these levels. I think your looking at least a 40% upside if an offer comes in.

I have to question the timing and reasoning of the trading update, Spire have never released a December update in previous years and they must have known it would have a negative impact on the market capital whilst undergoing a potential offer process. Seems strange, was it an attempt to lure more potential suitors with a lower valuation which doesn't fit with the logic of the strategic review or just to a dampen shareholders expectations RNS or let a suitor buy up a shedload or retail investors shares at a knockdown price ?

Revenue £2 Billion, current NAV £1 Billion, Cash £266 million but a measly Market Cap of £81m...this is either the bargain of a lifetime or something is seriously amiss here. Surely the Malaysian 27% shareholders must be considering a low ball bid.

I agree, because of the upcoming funding requirement the share price is at a hugely discounted level considering the many millions pumped in over the years covering R&D, clinical trials, FDA clearance etc..blimey if this product is as good as it seems to be then surely even a reasonably small profitable pharma company could be doing doing due diligence over this train wreck at this given moment. Could be the opportunity of a lifetime if anyone could eventually monetise Parsortix.

This is what happens when you put intellects in charge of branding, the new name tries to incorporate the directive of the company but the lacks presence and creativity.